Research article · 15 May 2026
Short communicationPublished 22 Jan 2021
Antiparkinsonian potential of cilostazol: insights into its neuroprotective effects
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Cilostazol, a 2-oxo-quinoline derivative, is a selective inhibitor of phosphodiesterase-3 that increases intracellular cAMP levels and activates protein kinase A. Cilostazol exhibited neuroprotection in focal cerebral ischemia in rats, which was attributed to its anti-apoptotic properties. Furthermore, it guarded against hypoperfusion-induced cognitive impairment resulting in protective activity in an animal model of vascular dementia. Interestingly, cilostazol proved to exert favourable effects against Alzheimer’s disease where it enhanced β-amyloid peptide degradation through autophagy modulation in N2a neuronal cells. Together, these findings further support the notion that cilostazol may possess neuroprotective effect and may show beneficial outcome in PD. The aim of this study is to explore the Neuroprotective effect of cilostazol in rotenone-induced PD model in rats. Parkinsonian rat pre-treated with cilostazol showed minimal neuronal vacuolation and minimal perivascular edema in the midbrain and striatum. Moreover, Pre-treatment of rats with cilostazol improved the motor deficits as verified by a remarkable surge in ambulation and rearing. This could be explained by the fact that cilostazol significantly raised striatal TH content as compared to the rotenone group. . In conclusion, cilostazol could be a promising candidate for PD treatment.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Oncology Translational Research.
Research article · 15 Dec 2025
Cardiac Substructure Analysis of Radiation-associated Cardiac Disease in Thoracic Malignancy Patients
Brief report · 29 Nov 2025
CDx: Navigating Global Regulations for Precision Medicine
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Oncology Translational Research
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Shireen A. Hedya”
